PiCSO Therapy Reduces Infarct Size in STEMI Patients: Miracor Medical Announces New Publication at EuroPCR

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Miracor Medical SA announced today the clinical results from the physician-sponsored OxAMI-PiCSO study were published in the EuroIntervention journal and presented at the Hotline session of the EuroPCR conference by Dr. Giovanni Luigi De Maria, MD, the Heart Centre, Oxford University Hospitals, Oxford, UK.

The latest results, obtained with the PiCSO® Impulse System, contribute to the growing body of evidence supporting the use of the PiCSO System during stenting procedures to improve microcirculatory flow and perfusion of the infarcted area leading to a significantly smaller residual infarct size after AMI. Decreased infarct size after AMI has been shown to directly correlate with reduced mortality and hospitalizations for heart failure1. Additional results from the PiCSO in ACS study were presented during the conference by Dr. Mohaned Egred, MD, Freeman Hospital, Newcastle upon Tyne, UK, and show that PiCSO-treated patients have a statistically smaller infarct size compared to a group of propensity score matched control patients.

“These positive results show promise that the PiCSO System can be used safely and effectively as an adjunctive therapy during primary PCI,” explains Professor Adrian Banning, MD, Chief Investigator of the ongoing OxAMI-PiCSO study conducted at the Heart Centre, Oxford University Hospitals in Oxford, UK. “Results demonstrating PiCSO’s ability to reduce myocardial injury for STEMI patients is noticed at 24-hours post-procedure with the IMR technique. This therapy has the potential to change my practice for STEMI patients.”

“The OxAMI-PiCSO study is the second study to show that PiCSO reduces the myocardial damage in STEMI patients and I am pleased that this growing body of data further confirms the potential of our system to become standard practice for the treatment of STEMI patients,” says Olivier Delporte, CEO of Miracor Medical.

PiCSO therapy is provided during the stenting procedure of patients enduring acute myocardial infarct (AMI) and intermittently increases pressure in the coronary venous system, which leads to an improved microcirculatory flow and improved perfusion of the infarcted area resulting in smaller residual infarct size after AMI compared to non-PiCSO treated patients.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.